COMPANY PROFILE

Constructive Bio

Explore full profile

Realising the potential of genome rewriting to drive the next generation of bioprocesses and biopharmaceuticals

Cambridge, United KingdomFounded 2021Biotech & Life Sciences

Valuation $250–500M Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Constructive Bio

Constructive Bio is a UK-based biotechnology company focused on re-engineering biology by creating synthetic genomes from scratch.

The company's core technology involves rewriting and reprogramming the genetic code of bacterial strains. By hijacking the cell's protein translation machinery, they can synthesize novel biopolymers and programmable biomolecules with high fidelity and scalability.

This capability allows for the creation of new classes of enzymes, pharmaceuticals, and biomaterials, targeting the drug discovery and biomanufacturing sectors.

The company operates on a B2B model, providing its technology for various commercial applications. Constructive Bio has secured significant venture funding, including a $15 million seed round and a $58 million Series A financing, to advance its genome synthesis platform.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: Cambridge, United Kingdom
Employees: 69
Open positions: 6
Dealroom signal: 92.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Synthetic Biology, Spinout, Industrial Technology, Advanced Materials, Bioeconomy, BIA Techbio UK, Techbio
Technology: Hardware, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Mar 2026	$20M	$284M	Undisclosed	↗
EARLY VCOther financing	Apr 2025	$0	—	LongeVC	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Constructive Bio website traffic

Latest recorded traffic for Constructive Bio is 7K monthly website visits, up 52.2% over the last three months. Constructive Bio's team grew 16.9% over the past year.

Latest monthly visits7K 3-month web change+52.2% 1-year team growth+16.9%

Monthly website visitsJan 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Speculative ApplicationsCambridge, United Kingdom, Northern Europe, Europe · Finance · Aug 23, 2026 Research Associate-Engineered TranslationCambridge, United Kingdom, Northern Europe, Europe · Other · Aug 9, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SYSynthaceEngineering biology for health, food, energy and manufacturing.	London, United Kingdom	Operational	35	$82M	$172M
BABactobioLondon-based biotechnology company using breakthrough technologies in synthetic biology	London, United Kingdom	Operational
TGTouchlight GeneticsDevelops a DNA production platform designed for the development of DNA vaccines for oncology and infectious diseases	London, United Kingdom	Operational
LALabGeniusCombining human and machine intelligence to accelerate the discovery of advanced medicines	London, United Kingdom	Operational
INIntellegensHelping clients accelerate innovation by using our unique deep learning solutions to extract valuable information from existing processes and data	Cambridge, United Kingdom	Operational
EBEpoch BiodesignDesigning and scaling the first enzymes capable of transforming plastics into low-carbon, circular chemicals	London, United Kingdom	Operational
EVEvonetixUr desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists' ability to use synthetic biology on a scale not currently possible	Cambridge, United Kingdom	Operational
CACardiaTecApplying artificial intelligence on large-scale human multiomic data to develop the next generation of cardiovascular disease targets	Cambridge, United Kingdom	Operational